Hereditary Angioedema (HAE) References

pdfASCIA HP Hereditary Angioedema (HAE) References 2020146.25 KB  

Agostoni, A. & Cicardi, M., (1992). Hereditary and acquired C1-inhibitor deficiency: biological and clinical characteristics in 235 patients. Medicine, 71(4), 206-215. https://journals.lww.com/md-journal/Citation/1992/07000/Hereditary_and_Acquired_C1_Inhibitor_Deficiency_.3.aspx

Agostoni, A., Cicardi, M., Cugno, M., Zingale, L. C., Gioffre, D., & Nussberger, J. (1999). Angioedema due to angiotensin-converting enzyme inhibitors. Immunopharmacology, 44 (1-2), 21–25. https://doi.org/10.1016/s0162-3109(99)00107-1

Agostoni, A., Aygoren-Pursun, E., Binkley, K.E., Blanch, A., Bork, K., Bouillet, L., … Zingale, L. (2004). Hereditary and acquired angioedema: problems and progress: proceedings of the third C1 esterase inhibitor deficiency workshop and beyond. Journal of Allergy and Clinical Immunology,114 (3 Suppl), S51-131. https://doi.org/10.1016/j.jaci.2004.06.047

Aygören-Pürsün, E., Bygum, A., Grivcheva-Panovska, V., Magerl, M., Graff, J., Steiner, U. C., … Cicardi, M. (2018). Oral Plasma Kallikrein Inhibitor for Prophylaxis in Hereditary Angioedema. New England Journal of Medicine, 379(4), 352-362. https://www.nejm.org/doi/full/10.1056/NEJMoa1716995

Baumgart, K. W., Britton, W. J., Kemp, A., French, M., & Robertson D. (1997). The spectrum of primary immunodeficiency disorders in Australia. Journal of Allergy and Clinical Immunology, 100(3), 415-423. https://doi.org/10.1016/S0091-6749(97)70257-4

Bell, C. G., Kwan, E., Nolan, R. C., &Baumgart, K. W. (2008). First molecular confirmation of an Australian case of type III hereditary angioedema. Pathology, 40(1), 82-83. https://journals.lww.com/pathologyrcpa/Citation/2008/40010/First_molecular_confirmation_of_an_Australian_case.15.aspx

Bernstein, J. A., Levy, R., Wasserman, A. Bewtra, A., Hurewitz, D., Obtulowicz, K., … Craig, T. J., (2008). Treatment of Acute Abdominal and Facial Attacks of Hereditary Angioedema (HAE) with Human C1-Esterase Inhibitor (C1-INH): Results of a Global, Multicenter, Randomized, Placebo-controlled, Phase II /III Study (I.M.P.A.C.T.1). Journal of Allergy and Clinical Immunology, 121(3), 795. https://doi.org/10.1016/j.jaci.2008.01.052

Bonner, N., Abetz-Webb, L., Renault, L., Caballero, T., Longhurst, H., Maurer, M., Christiansen, S., & Zuraw, B. (2015). Icatibant Outcome Survey (IOS) International Executive Committee and the Hereditary Angioedema Association (HAEA) Medical Advisory Board. Health Qual Life Outcomes, 13, 92.  https://doi.org/10.1186/s12955-015-0292-7

Bork, K., Barnstedt, S., Koch, P., & Traupe, H. (2000). Hereditary angioedema with normal C1-inhibitor activity in women. Lancet, 356 (9225), 213-217. https://doi.org/10.1016/S0140-6736(00)02483-1

Bork, K., Siedlecki, K., Bosch, S., Schopf, R.E., & Kreuz, W. (2000). Asphyxiation by laryngeal edema in patients with hereditary angioedema. Mayo Clinical Procedures, 75(4), 349-354. https://doi.org/10.4065/75.4.349

Bork, K., & Barnstedt, S. (2001). Treatment of 193 episodes of laryngeal oedema with C1-INH concentrate in patients with hereditary angioedema. Archives of Internal Medicine, 161(5), 714-718. https://doi.org/10.1001/archinte.161.5.714

Bork, K., Hardt, J., Schicketanz, K. H., & Ressel, N. (2003). Clinical Studies of Sudden Upper Airway Obstruction in Patients with Hereditary Angioedema Due to C1 Esterase Inhibitor Deficiency. Archives of Internal Medicine, 163(10), 1229–1235. https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/215579

Bork, K., Staubach, P., Eckardt, A. J., & Hardt, J. (2006). Symptoms, course, and complications of abdominal attacks in hereditary angioedema due to C1 inhibitor deficiency. American Journal of Gastroenterology, 101(3), 619-627. https://www.researchgate.net/deref/http%3A%2F%2Fdx.doi.org%2F10.1111%2Fj.1572-0241.2006.00492.x

Bork, K., Meng, G., Staubach, P., & Hardt, J. (2006). Hereditary Angioedema: new findings concerning symptoms, affected organs, and course. American Journal of Medicine, 119(3), 267-274. https://doi.org/10.1016/j.amjmed.2005.09.064

Bork, K., Frank, J., Grundt, B., Schlattmann, P., Nussberger, J., & Kreuz, W. (2007). Treatment of acute edema attacks in hereditary angioedema with a bradykinin receptor-2 antagonist (Icatibant). Journal of Allergy and Clinical Immunology, 119(6),1497-1503. https://doi.org/10.1016/j.jaci.2007.02.012

Bork, K., Bygum, A., & Hardt, J. (2008). Benefits and risks of danazol in hereditary angioedema: a long-term survey of 118 patients. Annals Allergy Asthma Immunology, 100(2), 153-161. https://doi.org/10.1016/s1081-1206(10)60424-3

Bork, K., Wulff, K., Witzke, G., & Hardt, J. (2017). Treatment for hereditary angioedema with normal C1-INH and specific mutations in the F12 gene (HAE-FXII).  Allergy, 72, 320-324. https://doi.org/10.1111/all.13076

Bouillet, L., Longhurst, H., Boccon-Gibod, I., Bork, K., Bucher, C. Bygum, A. … Cicardi, M. (2008). Disease expression in women with hereditary angioedema. American Journal of Obstetrics and Gynecology. 199(5), 484.e1-e4. https://doi.org/10.1016/j.ajog.2008.04.034

Bowen, T., Cicardi, M., Bork, K., Zuraw, B., Frank, M., Ritchie, B., … Zhi, Y. X. (2008). Hereditary angioedema: a current state-of-the-art review, VII: Canadian Hungarian 2007 International Consensus Algorithm for the Diagnosis, Therapy and Management of Hereditary Angioedema. Annals of Allergy, Asthma & Immunology 100, S30-S40. https://doi.org/10.1016/s1081-1206(10)60584-4

Boyle, R.J., Nikpour, M., & Tang, M. L. (2005). Hereditary angio-oedema in children: a management guideline. Pediatric Allergy and Immunology, 16(4), 288-294. https://doi.org/10.1111/j.1399-3038.2005.00275.x

Brickman, C. M., Tsokos, G. C., Balow, J. E., Lawley, T. J., Santaella, M., Hammer, C.H., & Frank, M.M. (1986). Immunoregulatory diseases associated with hereditary angioedema: 1. Clinical manifestations of autoimmune disease. Journal of Allergy and Clinical Immunology, 77(5), 749–757. https://doi.org/10.1016/0091-6749(86)90424-0

Busse, P. J., Christiansen, S. C., Birmingham, J. M., Overbey, J. R., Banerji, A., Otani, I. M., … Zuraw, B. L. (2019). Development of a health-related quality of life instrument for patients with hereditary angioedema living in the United States. Journal of Allergy and Clinical Immunology in Practice. 7, 1679-1683. https://doi.org/10.1016/j.jaip.2018.11.042

Bygum, A., Andersen, K. E., & Mikkelsen, C. S. (2009). Self-administration of intravenous C1-inhibitor therapy for hereditary angioedema and associated quality of life benefits. European Journal of Dermatology, 19(2),147-151. https://www.jle.com/10.1684/ejd.2008.0603

Campbell, D. J., Krum, H., & Esler, M, D. (2005). Losartan increases bradykinin levels in hypertensive humans. Circulation, 111(3),315-320. https://doi.org/10.1161/01.CIR.0000153269.07762.3B

Chinniah, N., & Katelaris, C.H. (2009). Hereditary angioedema and pregnancy. Australian and New Zealand Journal of Obstetrics and Gynaecology, 49(1), 2-5. https://doi.org/10.1111/j.1479-828X.2008.00945.x

Cicardi, M., Bergamaschini, L., Cugno, M., Hack, E., Agostoni, G. & Agostoni, A. (1991).  Long-term treatment of hereditary angioedema with attenuated androgens: a survey of a 13-year experience. Journal of Allergy and Clinical Immunology, 87(4), 768-773. https://doi.org/10.1016/0091-6749(91)90120-D

Cicardi, M., Castelli, R., Zingale, L.C., & Agostini, A. (1997). Side effects of long-term prophylaxis with attenuated androgens in hereditary angioedema: comparison of treated and untreated patients. Journal of Allergy and Clinical Immunology, 99(2), 194-196. https://doi.org/10.1016/S0091-6749(97)70095-2

Cicardi, M., Zingale, L., Pappalardo, E., Folcioni, A., & Agostoni, A. (2003). Autoantibodies and lymphoproliferative diseases in acquired C1-inhibitor deficiencies. Medicine (Baltimore) 82(4), 274–281. https://doi.org/10.1097/01.md.0000085055.63483.09

Craig, T., Zuraw, B., Longhurst, H., Cicardi, M., Bork, K., Grattan, C., … Jacobs, I. (2019). Long-Term Outcomes with Subcutaneous C1-Inhibitor Replacement Therapy for Prevention of Hereditary Angioedema Attacks. Journal of Allergy and Clinical Immunology in Practice, 7(6), 1793–1802.  https://doi.org/10.1016/j.jaip.2019.01.054

Davis, A. E. (2008). Hereditary angioedema: a current state-of-the-art review, III: mechanisms of hereditary angioedema. Annals of Allergy Asthma and Immunology, 100 (1 Suppl 2), S7-12. https://doi.org/10.1016/S1081-1206(10)60580-7

Deald, G., & Bork, K. (2006). Missense mutations in the coagulation factor XII (Hageman factor) gene in hereditary angioedema with normal C1 inhibitor. Biochemical and Biophysical Research Communications, 343(4), 1286-1289. https://doi.org/10.1016/j.bbrc.2006.03.092

Donaldson, V. H., & Evans, R. R. (1963). A biochemical abnormality in hereditary angioneurotic edema: absence of serum inhibitor of C’ 1-esterase. American Journal of Medicine, 35, 37-44. https://doi.org/10.1016/0002-9343(63)90162-1

Donaldson, V. H., Rosen, F. S. (1964). Action of complement in hereditary angioedema: the role of C’1-esterase. Journal of Clinical Investigation, 4, 2204–2213.https://doi.org/10.1172/JCI105094

Farkas, H., Harmat, G., Füst, G., Varga, L., & Visy, B. (2002). Clinical management of hereditary angio-oedema in children. Pediatric Allergy and Immunology. 13(3), 153-161. https://doi.org/10.1034/j.1399-3038.2002.01014.x

Farkas, H., Varga, L., Szeplaki, G., Visy, B., Harmat, G., & Bowen, T. (2007). Management of hereditary angioedema in pediatric patients. Pediatrics, 120(3), e713-722. https://doi.org/10.1542/peds.2006-3303

Farkas, H., Czaller, I., Csuka, D., Vas, A., Valentin, S., Varga, … & Karádi I. (2010). The effect of long-term danazol prophylaxis on liver function in hereditary angioedema-a longitudinal study. Eur J Clin Pharmacol, 66(4), 419-42. https://link.springer.com/article/10.1007/s00228-009-0771-z

Frank, M. M., Gelfand, J.A., & Atkinson, J.P. (1976). Hereditary angioedema: the clinical syndrome and its management. Annals of Internal Medicine, 84, 580-93. https://doi.org/10.7326/0003-4819-84-5-580

Frank, M. M. (1979). Effect of sex hormones on the complement-related clinical disorder of hereditary angioedema. Arthritis and Rheumatism, 22(11),1295–1299. https://doi.org/10.1002/art.1780221118

Frank, M. M. (2000). Urticaria and angioedema in Goldman, L. & Bennett, J. C., (ed) Cecil Textbook of Medicine. 21 ed. W. B. Saunders Co 1440-1445.

Frank, M. M. (2006). Hereditary angioedema: the clinical syndrome and its management in the United States. Immunology and Allergy Clinics of North America, 26(4), 653-668. https://doi.org/10.1016/j.iac.2006.09.005

Frank, M. M. (2008). Hereditary angioedema: a current state-of-the-art review, VI: novel therapies for hereditary angioedema. Annals of Allergy Asthma and Immunology, 100(1 Suppl 2), S23-29. https://doi.org/10.1016/S1081-1206(10)60583-2

Gompels, M. M., Lock, R. J., Abinun, M., Bethune, C. A., Davies, G., Grattan, C., … Watters, D. (2005). C1 inhibitor deficiency: consensus document. Clinical and Experimental Immunology, 139(3), 379-394. https://doi.org/10.1111/j.1365-2249.2005.02726.x

Graves, R. (1843). Clinical lectures on the practice of medicine, in Major, R.H., ed. (1955). Classic Descriptions of Disease. 3rd Ed. Charles C. Thomas Pub Ltd, 623- 624.

Jurado-Palomo, J., Muñoz-Caro, J. M., López-Serrano, M. C., Prior, N., Cabañas, R., Pedrosa, M., Burgueño, M., & Caballero, T. (2013). Management of Dental-Oral Procedures in Patients with Hereditary Angioedema due to C1 Inhibitor Deficiency.  The Journal of Investigational Allergology and Clinical Immunology, 23(1), 1-6. http://www.jiaci.org/issues/vol23issue1/1.pdf

Landerman, N. S., Webster, M. E., Becker, E. L., & Ratcliffe, H. E. (1962). Hereditary angioneurotic edema. Journal of Allergy, 33, 330–341. https://doi.org/10.1016/0021-8707(62)90031-X

Longhurst, H. J. (2005). Emergency treatment of acute attacks in hereditary angioedema due to C1 inhibitor deficiency: what is the evidence? International Journal of Clinical Practice, 59(5), 594-599. https://doi.org/10.1111/j.1742-1241.2005.00352.x

Longhurst, H., Cicardi, M., Craig, T., Bork, K., Grattan, C., Baker, J., … Zuraw, B. L. for COMPACT Investigators. (2017). Prevention of Hereditary Angioedema Attacks with a Subcutaneous C1 Inhibitor. New England Journal of Medicine, 376, 1131–40. https://www.nejm.org/doi/pdf/10.1056/NEJMoa1613627

Magerl, M., Germenis, A. E., Maas, C., & Maurer, M. (2017). Hereditary Angioedema with Normal C1 Inhibitor: Update on Evaluation and Treatment.  Immunology and Allergy Clinics of North America, 37(3), 571-584. https://doi.org/10.1016/j.iac.2017.04.004

Maurer, M., Longhurst, H. J., Fabien, V., Li, H. H., & Lumry, W. R., for the IOS Study Group. (2014). Treatment of hereditary angioedema with icatibant: efficacy in clinical trials versus effectiveness in the real-world setting. Allergy Asthma Proc, 35(5), 377-81.  https://doi.org/10.2500/aap.2014.35.3780

Maurer, M., Magerl, M., Ansotegui, I., Aygoren-Pursun, E., Betschel, S., Bork, K. … Craig, T. (2018). The international WAO/EAACI guideline for the management of hereditary angioedema – the 2017 revision and update. World Allergy Organization Journal, 11, Article number 5. https://doi.org/10.1186/s40413-017-0180-1

Nzeako, U. C., Frigas, E., & Tremaine, W. J. (2001). Hereditary angioedema: a broad review for clinicians. Archives of Internal Medicine, 161, 2417-2429. https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/649449

O'Bier, A., Muniz, A.E., & Foster, R.L. (2005). Hereditary angioedema presenting as epiglottitis. Pediatric Emergency Care, 21(1), 27-30. https://doi.org/10.1097/01.pec.0000150985.81109.0d

Osler, W. (1988). Hereditary angio-neurotic oedema. American Journal of Medical Science, 95, 362–367. https://doi.org/10.1186/1471-2326-10-3

Postnikoff, I. M. & Pritzker, K. P. (1979). Hereditary angioneurotic edema: an unusual case of maternal mortality. Journal of Forensic Sciences, 24, 473-478. https://doi.org/10.1520/JFS10855J

Prematta, M. J., Prematta, T., & Craig, T. J. (2008). Treatment of HAE with plasma-derived C1inhibitor. Therapeutics & Clinical Risk Management, 4(5), 1-8. https://doi.org/10.2147/TCRM.S3172

Prior, N., Remor, E., Gomez-Traseira, C., Lopez-Serrano, C., Cabanas, R., Contreras, J., … Cabereloo, T.  (2012). Development of a disease-specific quality of life questionnaire for adult patients with hereditary angioedema due to C1 inhibitor deficiency (HAE- QoL): Spanish multi-centre research project. Health Qual Life Outcomes, 10, 82.  https://doi.org/10.1186/1477-7525-10-82

Quincke, H. (1882). Concerning the acute localized oedema of the skin. Monatsh Prakt Dermatology, 1, 129–31.

Roche, O., Blanch, A., Caballero, T., Sastre, N., Callejo, D., & Lopez-Trascasa, M. (2005). Hereditary angioedema due to C1 inhibitor deficiency: patient registry and approach to the prevalence in Spain. Annals of Allergy, Asthma, & Immunology, 94, 498-503. https://doi.org/10.1016/S1081-1206(10)61121-0

Rosen, F. S., Pensky, J., Donaldson, V., & Charache, P. (1965). Hereditary angioneurotic edema: two genetic variants. Science, 148, 957–958. https://doi.org/10.1126/science.148.3672.957

Szeplaki, G., Varga, L., Kleiber, M., Karadi, I., Romics, L., Fust, G., & Farkas, H. (2005). Adverse effects of danazol prophylaxis on the lipid profiles of patients with hereditary angioedema. Journal of Allergy and Clinical Immunology, 115, 864-869. https://doi.org/10.1016/j.jaci.2004.12.1130

Weller, K., Groffik, A., Magerl, M., Tohme, N., Martus, P., Krause, K., …  Maurer, M. (2012). Development and construct validation of the angioedema quality of life questionnaire. Allergy, 67(10),1289–98.  https://doi.org/10.1111/all.12007

Weller, K., Magerl, M., Peveling-Oberhag, A., Martus, P., Staubach, P., & Maurer, M. (2016). The Angioedema Quality of Life Questionnaire (AE-QoL) - assessment of sensitivity to change and minimal clinically important difference. Allergy, 71,1203–9. https://doi.org/10.1111/all.12900

Winnewisser, J., Rossi, M., Späth, P., & Bürgi, H. (1997). Type I hereditary angio-oedema. Variability of clinical presentation and course within two large kindreds. Journal of Internal Medicine, 241(1). https://doi.org/10.1046/j.1365-2796.1997.76893000.x

Wu, M. A. Lanadelumab for the treatment of hereditary angioedema. (2019). Expert Opinion on Biological Therapy. 19, 1233–45.  https://doi.org/10.1080/14712598.2019.1685490

Zingale, L. C., Beltrami, L., Zanichelli, A., Maggioni, L., Pappalardo, E., Cicardi, B., & Cicardi, M. (2006). Angioedema without urticaria: a large clinical survey. Canadian Medical Association Journal, 175, 1065-1070. https://doi.org/10.1503/cmaj.060535

Zuraw, B. L. & Herschbach, J., (2000). Detection of C1 inhibitor mutations in patients with hereditary angioedema. Journal of Allergy Clinical Immunology, 105(3), 541-546. https://doi.org/10.1067/mai.2000.104780

Zuraw, B. L. (2008). Clinical practice. Hereditary angioedema. New England Journal of Medicine, 359, 1027-1036. http://doi.org/10.1056/NEJMcp0803977

Zuraw, B. L. (2018). Hereditary angioedema with normal C1 inhibitor: Four types and counting. J Allergy Clin Immunol. 141(3), 884-5. https://doi.org/10.1016/j.jaci.2018.01.015

Zuraw B. L.,  Lumry, W., Banerji, A., Aygoren-Pursun, E., Bernstein, J., Johnston, D. … Sheridan, W. (2019). P150 oral prophylaxis with bcx7353 reduces HAE attack rates and is well-tolerated: apex-2 study results.  Annals Allergy Asthma & Immunol, 123(5), S27. https://www.annallergy.org/article/S1081-1206(19)30843-9/fulltext

NOTE: There is a separate ASCIA reference list for Immunodeficiency publications on the ASCIA website www.allergy.org.au/hp/papers#p4

Content updated October 2020 

Mod ASCIA Member
Donate to AIFA
go to NAS website
Member Login
ASCIA Update

Information for the community about allergic diseases, immunodeficiencies and other immune diseases.
See latest edition here...
Join our mailing list:

About ASCIA

ASCIA is the peak professional body of clinical immunology and allergy in Australia and New Zealand
ASCIA promotes and advances the study and knowledge of allergy and other immune diseases

Quick Links

About ASCIA

ASCIA is a registered trademark of the Australasian Society of Clinical Immunology and Allergy. All content is subject to copyright for the Australasian Society of Clinical Immunology and Allergy. Read more...

The content for the website is developed and approved by ASCIA Committee and ASCIA Working Party Members. Read more...

Disclaimer I Privacy

The ASCIA website is intended for use by ASCIA members, health professionals and the general public. The content provided is for education, communication and information purposes only and is not intended to replace or constitute medical advice or treatments. Read more...

ASCIA respects your privacy. Read our privacy policy here...

Sponsors | Advertising

ASCIA does not endorse products from sponsoring organisations, nor is it influenced by sponsoring organisations with regard to the content of education programs and websites. 

The ASCIA website does not accept advertising. Any link to a third-party website does not imply any endorsement by ASCIA.

Accreditiation

healthdirect

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information: verify here.